Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

Phase 4

1(20.0%)

5Total

N/A(2)

Phase 2(1)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07748039Phase 3Not Yet Recruiting

Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events

Role: lead

NCT06492265Phase 2Recruiting

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-B )

Role: lead

NCT02140658Not ApplicableCompleted

Affect of Health Education on Statins Medication Persistence and ClinicaL Prognosis of Ischemic Stroke Patients (HELP)

Role: lead

NCT02140619Not ApplicableCompleted

Affect of Multiple Health Education on Medication Persistence and Clinical Prognosis of Ischemic Stroke Patients

Role: lead

NCT01919671Phase 4Completed

Tongxinluo Capsule in Ischemic Stroke Patients（TISS)

Role: lead

NCT02156765Unknown

China Atrial Fibrillation Screening in Acute Ischemic Stroke Patients

Role: lead

NCT01556854Unknown

Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke

Role: lead

All 7 trials loaded